You are here
Phase 2 Trial of KOS-862 in Non-Small Cell Lung Cancer Halted
"Although we have concluded the non-small cell lung cancer trial, the response rate of patients with prostate and breast cancers towards other epothilones leads us to be optimistic about the potential efficacy of KOS-862 in these types of tumors," said Daniel V. Santi, M.D., Ph.D., Chairman and Chief Executive Officer of Kosan.
William M. Burns, Head of Roche's Pharmaceuticals Division, added, "We are learning about this class of drugs and Roche will continue to work with Kosan on the development of KOS-862 for other indications, as well as advancing next-generation epothilone analogs through the pipeline."
Roche and Kosan entered into a global alliance for the co-development and commercialization of KOS-862 and its back up compounds in September 2002.
Source: Kosan Biosciences